Structural Genomics Consortium

Last updated

The Structural Genomics Consortium (SGC) is a public-private-partnership focusing on elucidating the functions and disease relevance of all proteins encoded by the human genome, with an emphasis on those that are relatively understudied. [1] [2] [3] The SGC places all its research output into the public domain without restriction and does not file for patents and continues to promote open science. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Two recent publications revisit the case for open science. [15] [16] Founded in 2003, and modelled after the Single Nucleotide Polymorphism Database (dbSNP) Consortium, the SGC is a charitable company whose Members comprise organizations that contribute over $5,4M Euros to the SGC over a five-year period. The Board has one representative from each Member and an independent Chair, who serves one 5-year term. The current Chair is Anke Müller-Fahrnow (Germany), and previous Chairs have been Michael Morgan (U.K.), Wayne Hendrickson (U.S.A.), Markus Gruetter (Switzerland) and Tetsuyuki Maruyama (Japan). The founding and current CEO is Aled Edwards (Canada). The founding Members of the SGC Company were the Canadian Institutes of Health Research, Genome Canada, the Ontario Research Fund, GlaxoSmithKline and Wellcome Trust. The current (March 2022) Members comprise Bayer Pharma AG, Bristol Myers Squibb, Boehringer Ingelheim, the Eshelman Institute for Innovation, Genentech, Genome Canada, Janssen, Merck KGaA, Pfizer, and Takeda.

Contents

SGC research activities take place in a coordinated network of university-affiliated laboratories – at Goethe University Frankfurt, Karolinska Institutet, McGill University, and the Universities of North Carolina at Chapel Hill and Toronto. The research activities are supported both by funds from the SGC Company as well as by grants secured by the scientists affiliated with the SGC programs. At each university, the scientific teams are led by a Chief Scientist, who are Stefan Knapp (Goethe University Frankfurt), Michael Sundstrom (Karolinska Institutet), Ted Fon (McGill University), Tim Willson (University of North Carolina at Chapel Hill), and Cheryl Arrowsmith (University of Toronto). The SGC currently comprises ~200 scientists.

Notable achievements

Chemical biology of human proteins

Structural biology of human proteins – The SGC has so far contributed over 2000 protein structures of human proteins of potential relevance for drug discovery into the public domain since 2003. [17] Structures that constitute complexes with synthetic small molecules is aided by a partnership with the Diamond synchrotron in Oxfordshire. [18] The chemical probe program prioritizes (members of) protein families that are relatively understudied, or which may be currently relevant to human biology and drug discovery. These families include epigenetic signaling, [19] [20] solute transport, [21] [22] protein proteostasis, [23] [24] [25] [26] [27] and protein phosphorylation. [12] [28] [29] The protein family approach is supported by publicly available bioinformatics tools (ChromoHub, [30] UbiHub [31] ), family-based protein production and biochemistry, crystallography and structure determination, biophysics, and cell biology (for example target engagement assays). The SGC has (so far) contributed ~120 chemical probes [10] [32] [33] into the public domain over the past decade, and >25,000 samples of these probes have been distributed to the scientific community. The chemical probes conform to the now community-standard quality criteria created by the SGC and its collaborative network. [10] [34] [35] [36] [37] [38]

  1. Epigenetic chemical probes that have generated clinical interest in their targets include PFI-1 [39] and JQ1 [40] for the BET family, UNC0642 [41] for G9a/GLP, UNC1999 [42] for EZH2/H1, LLY-283 [43] and GSK591 [44] for PRMT5, and OICR-9429 [45] for WDR5. The WDR5 chemical probe was optimized (by a company external to the SGC) for clinical amenability and is the subject of investment from Celgene.
  2. Kinases have seen 50 drugs approved by the FDA for treatment of cancer, inflammation, and fibrosis. [46] A review [47] from two and a half years ago, a recent preprint, [48] and peer-reviewed publication [49] highlight low coverage of kinases both by peer-reviewed publications and 3D structures. In the last 4 years laboratories in Frankfurt, North Carolina and Oxford have developed chemical matter to help biologists study underrepresented kinases. In collaboration with pharmaceutical companies and academia, 15 chemical probes, and version 1.0 of 187 chemogenomic inhibitors (aka KCGS) for 215 kinases [12] [29] have been co-developed.
  3. Integral membrane proteins are permanently attached to the cell membrane. The family includes the solute carrier (SLC) proteins. The SLCs are largely unexplored therapeutically ~30% are considered ‘orphaned’ because their substrate specificity and biological function are unknown. In 2019 a public-private partnership comprising 13 partners, including the SGC, formed The RESOLUTE Consortium [22] with funding from the IMI. RESOLUTE’s goal is to encourage research on SLCs .
  4. The Target Enabling Package (TEP) is a collection reagents and knowledge on a protein target aimed to catalyze biochemical and chemical exploration, and characterization of proteins with genetic linkage to key disease areas. The SGC has opened target nominations to the public. [50]
  5. The Unrestricted Leveraging of Targets for Research Advancement and Drug Discovery (ULTRA-DD) program, funded by the European Commission’s Innovative Medicines Initiative (IMI), aims to identify and validate under-explored targets in auto-immune and inflammatory disease models. Patient-derived cell lines are screened against chemical modulators (including chemical probes and chemogenomic compounds) with the intention of obtaining phenotypic read-outs in a disease relevant context. [51]
  6. The Enabling and Unlocking biology in the Open (EUbOPEN) program, funded by the IMI, aims to assemble a chemogenomic library for ~1,000 proteins, discover ~100 high-quality, chemical probes, establish infrastructure to characterize these compounds, disseminate robust protocols for primary patient cell-based assays, while establishing the infrastructure to seed a global effort on addressing the entire druggable genome.

Non-human proteins

The Structure-guided Drug Discovery Coalition (SDDC) comprises the Seattle Structural Genomics Center for Infectious Disease (SSGCID), the Midwest Center for Structural Genomics, the Center for Structural Genomics of Infectious Diseases (CSGID), and drug discovery teams from academia and industry has resulted in 7 early drug leads for tuberculosis (TB), malaria, and cryptosporidiosis. The SDDC receives funding from participating academic initiatives and the Bill & Melinda Gates Foundation.

The University of North Carolina at Chapel Hill and the Eshelman Institute for Innovation, launched Rapidly Emerging Antiviral Drug Development Initiative (READDI™) and Viral Interruption to Medicines Initiative (VIMI™). REDDI™ is modelled after the non-profit drug research and development Drugs for Neglected Diseases Initiative (DNDi). READDI™ and VIMI™ are non-profit, open science initiatives that focus on developing therapeutics for all pandemic-capable viruses. [52]

Open Science

Open science is a key operating principle. [53] A Trust Agreement [4] [5] [6] [54] is signed before reagents are shared with researchers. These reagents include cDNA clones (Addgene), chemical probes, [55] and 3D structures. [17] Tools to promote open science include open lab notebooks. [9] The latter platform is being used to share research on (for example) Diffuse intrinsic pontine glioma (DIPG), Fibrodysplasia ossificans progressiva, Huntington’s disease, [8] [56] Parkinson’s disease, and Chordoma.

Open Drug Discovery

The for-profit spin-off companies M4K Pharma (Medicines for Kids), M4ND Pharma (Medicines for Neurological Diseases) and M4ID Pharma (Medicines for Infectious Diseases) do not file patents and practise open science. The M4 companies are wholly owned by a Canadian charity Agora Open Science Trust whose mandate is to share scientific knowledge and ensure affordable access to all medicines. M4K Pharma has the most advanced open drug discovery program [14] and is supported with funding from the Ontario Institute for Cancer Research, The Brain Tumour Charity, Charles River Laboratories and Reaction Biology, and with contributions from scientists at the Universities of McGill, North Carolina, Oxford, Pennsylvania, and Toronto and in the Sant Joan de Déu hospital, the University Health Network hospitals, the Hospital for Sick Children, and The Institute for Cancer Research. M4K Pharma is developing a selective inhibitor of ALK2 for DIPG, a uniformly fatal pediatric brain tumour. [14]

History

The Concept

In 2000, a group of companies and Wellcome conceptualized forming a Structural Genomics Consortium to focus on determining the three-dimensional structures of human proteins. [1] The consortium must place all structural information and supporting reagents into the public domain without restriction. This effort was designed to complement other structural genomics programs in the world.

Phase I (2004-2007)

The SGC scientific program was launched, with activities at the Universities of Oxford and Toronto, and with a mandate to contribute >350 human protein structures into the public domain. To be counted toward these goals, the proteins had to derive from a pre-defined list and the protein structures were required to meet pre-defined quality criteria. The quality of protein structures was and continues to be adjudicated by a committee of independent academic scientists. Michael Morgan was the Chair of the SGC Board, and the scientific activities were led by Cheryl Arrowsmith (Toronto) and Michael Sundstrom (Oxford). In mid 2005, VINNOVA, the Knut and Alice Wallenberg Foundation and the Foundation for Strategic Research (SSF) established the Swedish research node of the SGC. Experimental activities started at the Karolinska Institutet in Stockholm, led by Pär Nordlund and Johan Weigelt. Together, the three SGC laboratories contributed 392 human protein structures into the public domain. A pilot program in the structural biology of proteins in the malaria parasite was also initiated. [57]

Phase II (2007-2011)

The new goal for structures was 650. The SGC focused considerable activities in the areas of ubiquitination, protein phosphorylation, small G-proteins and epigenetics, and also initiated an effort in the structural biology of integral membrane proteins. In this phase, the SGC determined the structures of 665 human proteins from its Target List. With support from Wellcome and GSK, the SGC launched a program to develop freely-available chemical probes to proteins involved in epigenetic signalling which at the time were under studied. [2] [5] The quality of each chemical probe was subject to two levels of review prior to their dissemination to the public. The first was internal, through a Joint Management Committee comprising representatives from each member organization. The second was provided by a group of independent experts selected from academia. This level of oversight is aimed at developing reagents that support reproducible research. [58] [59] [13] It ultimately led to the creation of the Chemical Probes Portal. The SGC Memberships expanded to include Merck, Sharpe and Dohme, and Novartis. Wayne Hendrickson served as the Chair of the SGC Board.

Phase III (2011-2015)

The SGC mandate diversified to include 200 human proteins including 5 integral membrane proteins and chemical probes (30). Many of the chemical probes’ programs were undertaken in partnership with scientists in the pharmaceutical companies, which made the commitment to contribute the collaborative chemical probe into the public domain, without restriction. In Phase III, the SGC, along with the SSGCID (https://www.ssgcid.org/) and the CSGID (https://csgid.org/) launched the SDDC. SGC Memberships: AbbVie, Bayer AG, Boehringer Ingelheim, Eli Lilly and Janssen. Merck, Sharpe and Dohme and the Canadian Institutes for Health Research left the consortium. Markus Gruetter became the Chair of the SGC Board.[ citation needed ] [60]

Phase IV (2015-2020)

This phase built on the goals of previous phases but included well-characterized antibodies to human proteins. The SGC initiated a concerted effort to develop disease-relevant, cell-based assays using (primary) cells or tissue from patients. This phase saw the launch of research activities at Goethe University in Frankfurt, at McGill University, and at the Universities of Campinas and North Carolina, and participation in ULTRADD and RESOLUTE [21] [22] within IMI. SGC Memberships: Merck KGaA, the Eshelman Institute for Innovation, Merck, Sharpe and Dohme joined while GSK and Eli Lilly left. Tetsuyuki Maruyama became the Chair of the Board.[ citation needed ]

The Future - Target 2035

Target 2035 is an open science movement with the goal of creating chemical [12] [24] [29] [32] [33] and/or biological [13] [59] tools for the entire proteome by 2035. [61] The launch in November 2020 and monthly webinars have and continue to be free to attend. Supporting projects currently underway include the SGC’s epigenetics chemical probe program, [62] [63] [64] the NIH’s Illuminating the Druggable Genome initiative for under-explored kinases, GPCR’s and ion channels, [65] [66] [67] IMI’s RESOLUTE project on human SLCs, [22] and IMI's Enabling and Unlocking Biology in the Open (EUbOPEN). These teams are linked to SGC’s global collaborative network. [2] [10] [35] [51] [68] [13] [59]

Selected publications

Chemogenomics, protein degradation

Patient-derived cell assays

Open science

Reproducibility

Related Research Articles

A biological target is anything within a living organism to which some other entity is directed and/or binds, resulting in a change in its behavior or function. Examples of common classes of biological targets are proteins and nucleic acids. The definition is context-dependent, and can refer to the biological target of a pharmacologically active drug compound, the receptor target of a hormone, or some other target of an external stimulus. Biological targets are most commonly proteins such as enzymes, ion channels, and receptors.

Chemical biology is a scientific discipline between the fields of chemistry and biology. The discipline involves the application of chemical techniques, analysis, and often small molecules produced through synthetic chemistry, to the study and manipulation of biological systems. In contrast to biochemistry, which involves the study of the chemistry of biomolecules and regulation of biochemical pathways within and between cells, chemical biology deals with chemistry applied to biology.

<span class="mw-page-title-main">Chemogenomics</span>

Chemogenomics, or chemical genomics, is the systematic screening of targeted chemical libraries of small molecules against individual drug target families with the ultimate goal of identification of novel drugs and drug targets. Typically some members of a target library have been well characterized where both the function has been determined and compounds that modulate the function of those targets have been identified. Other members of the target family may have unknown function with no known ligands and hence are classified as orphan receptors. By identifying screening hits that modulate the activity of the less well characterized members of the target family, the function of these novel targets can be elucidated. Furthermore, the hits for these targets can be used as a starting point for drug discovery. The completion of the human genome project has provided an abundance of potential targets for therapeutic intervention. Chemogenomics strives to study the intersection of all possible drugs on all of these potential targets.

Aled Morgan Edwards is the founder and Chief Executive of the Structural Genomics Consortium, a charitable public-private partnership. He is Professor of Medical Genetics and Medical Biophysics at the University of Toronto, Visiting Professor of Chemical Biology at the University of Oxford, and Adjunct Professor at McGill University.

Cheryl H. Arrowsmith is a Canadian structural biologist and is the Chief Scientist at the Toronto laboratory of the Structural Genomics Consortium. Her contributions to protein structural biology includes the use of NMR and X-ray crystallography to pursue structures of proteins on a proteome wide scale.

A protein kinase inhibitor (PKI) is a type of enzyme inhibitor that blocks the action of one or more protein kinases. Protein kinases are enzymes that phosphorylate (add a phosphate, or PO4, group) to a protein and can modulate its function.

<span class="mw-page-title-main">MAPK7</span> Protein-coding gene in the species Homo sapiens

Mitogen-activated protein kinase 7 also known as MAP kinase 7 is an enzyme that in humans is encoded by the MAPK7 gene.

<span class="mw-page-title-main">LY294002</span> Chemical compound

LY294002 is a morpholine-containing chemical compound that is a potent inhibitor of numerous proteins, and a strong inhibitor of phosphoinositide 3-kinases (PI3Ks). It is generally considered a non-selective research tool, and should not be used for experiments aiming to target PI3K uniquely.

<span class="mw-page-title-main">ChEMBL</span> Chemical database of bioactive molecules also having drug-like properties

ChEMBL or ChEMBLdb is a manually curated chemical database of bioactive molecules with drug inducing properties. It is maintained by the European Bioinformatics Institute (EBI), of the European Molecular Biology Laboratory (EMBL), based at the Wellcome Trust Genome Campus, Hinxton, UK.

<span class="mw-page-title-main">Ming-Ming Zhou</span>

Ming-Ming Zhou is an American scientist who focuses on structural and chemical biology, NMR spectroscopy, and drug design. He is the Dr. Harold and Golden Lamport Professor and Chairman of the Department of Pharmacological Sciences. He is also the co-director of the Drug Discovery Institute at the Icahn School of Medicine at Mount Sinai and Mount Sinai Health System in New York City, as well as Professor of Sciences. Zhou is an elected fellow of the American Association for the Advancement of Science.

Chemical genetics is the investigation of the function of proteins and signal transduction pathways in cells by the screening of chemical libraries of small molecules. Chemical genetics is analogous to classical genetic screen where random mutations are introduced in organisms, the phenotype of these mutants is observed, and finally the specific gene mutation (genotype) that produced that phenotype is identified. In chemical genetics, the phenotype is disturbed not by introduction of mutations, but by exposure to small molecule tool compounds. Phenotypic screening of chemical libraries is used to identify drug targets or to validate those targets in experimental models of disease. Recent applications of this topic have been implicated in signal transduction, which may play a role in discovering new cancer treatments. Chemical genetics can serve as a unifying study between chemistry and biology. The approach was first proposed by Tim Mitchison in 1994 in an opinion piece in the journal Chemistry & Biology entitled "Towards a pharmacological genetics".

BET inhibitors are a class of drugs that reversibly bind the bromodomains of Bromodomain and Extra-Terminal motif (BET) proteins BRD2, BRD3, BRD4, and BRDT, and prevent protein-protein interaction between BET proteins and acetylated histones and transcription factors.

<span class="mw-page-title-main">Targeted covalent inhibitors</span>

Targeted covalent inhibitors (TCIs) or Targeted covalent drugs are rationally designed inhibitors that bind and then bond to their target proteins. These inhibitors possess a bond-forming functional group of low chemical reactivity that, following binding to the target protein, is positioned to react rapidly with a proximate nucleophilic residue at the target site to form a bond.

Polypharmacology is the design or use of pharmaceutical agents that act on multiple targets or disease pathways.

<span class="mw-page-title-main">Chemical Probes Portal</span>

The Chemical Probes Portal is an open, online resource whose purpose is to identify and make available high quality chemical probes for use in biological research and drug discovery. While chemical probes can be valuable tools to elucidate signal transduction pathways and to validate new drug targets, many of the probes that are in use are not selective and therefore can give very misleading results.

Jin Zhang is a Chinese-American biochemist. She is a professor of pharmacology, chemistry and biochemistry, and biomedical engineering at the University of California, San Diego.

<span class="mw-page-title-main">Bump and hole</span>

The bump-and-hole method is a tool in chemical genetics for studying a specific isoform in a protein family without perturbing the other members of the family. The unattainability of isoform-selective inhibition due to structural homology in protein families is a major challenge of chemical genetics. With the bump-and-hole approach, a protein–ligand interface is engineered to achieve selectivity through steric complementarity while maintaining biochemical competence and orthogonality to the wild type pair. Typically, a "bumped" ligand/inhibitor analog is designed to bind a corresponding "hole-modified" protein. Bumped ligands are commonly bulkier derivatives of a cofactor of the target protein. Hole-modified proteins are recombinantly expressed with an amino acid substitution from a larger to smaller residue, e.g. glycine or alanine, at the cofactor binding site. The designed ligand/inhibitor has specificity for the engineered protein due to steric complementarity, but not the native counterpart due to steric interference.

<span class="mw-page-title-main">Gerardo Turcatti</span> Swiss-Uruguayan chemical biologist and pharmacologist

Gerardo Turcatti is a Swiss-Uruguayan chemist who specialises in chemical biology and drug discovery. He is a professor at the École Polytechnique Fédérale de Lausanne (EPFL) and director of the Biomolecular Screening Facility at the School of Life Sciences there.

Target 2035 is a global effort or movement to discover open science, pharmacological modulator(s) for every protein in the human proteome by the year 2035. The effort is led by the Structural Genomics Consortium with the intention that this movement evolves organically. Target 2035 has been borne out of the success that chemical probes have had in elevating or de-prioritizing the therapeutic potential of protein targets. The availability of open access pharmacological tools is a largely unmet aspect of drug discovery especially for the dark proteome.

James Allen Wells is a Professor of Pharmaceutical Chemistry and Cellular & Molecular Pharmacology at the University of California, San Francisco (UCSF) and a member of the National Academy of Sciences. He received his B.A. degrees in biochemistry and psychology from University of California, Berkeley in 1973 and a PhD in biochemistry from Washington State University with Ralph Yount, PhD in 1979. He completed his postdoctoral studies at Stanford University School of Medicine with George Stark in 1982. He is a pioneer in protein engineering, phage display, fragment-based lead discovery, cellular apoptosis, and the cell surface proteome.

References

  1. 1 2 Williamson, AR (2000). "Creating a structural genomics consortium". Nature Structural Biology. 7: 953. doi:10.1038/80726. PMID   11103997. S2CID   35185565.
  2. 1 2 3 Edwards, AM; et, al. (2011). "Too many roads not taken". Nature. 470 (2333): 163–165. arXiv: 1102.0448 . Bibcode:2011Natur.470..163E. doi:10.1038/470163a. PMID   21307913. S2CID   4429387.
  3. ↑ Davis, Andrew M.; Engkvist, Ola; Fairclough, Rebecca J.; Feierberg, Isabella; Freeman, Adrian; Iyer, Preeti (2021-02-13). "Public-Private Partnerships: Compound and Data Sharing in Drug Discovery and Development". SLAS Discovery. 26 (5): 604–619. doi: 10.1177/2472555220982268 . ISSN   2472-5552. PMID   33586501. S2CID   231928371.
  4. 1 2 Edwards, Aled (September 2008). "Open-source science to enable drug discovery". Drug Discovery Today. 13 (17–18): 731–733. doi:10.1016/j.drudis.2008.04.011. ISSN   1359-6446. PMID   18790412.
  5. 1 2 3 Edwards, Aled M.; Bountra, Chas; Kerr, David J.; Willson, Timothy M. (July 2009). "Open access chemical and clinical probes to support drug discovery". Nature Chemical Biology. 5 (7): 436–440. doi:10.1038/nchembio0709-436. ISSN   1552-4469. PMID   19536100.
  6. 1 2 Masum, Hassan; Rao, Aarthi; Good, Benjamin M.; Todd, Matthew H.; Edwards, Aled M.; Chan, Leslie; Bunin, Barry A.; Su, Andrew I.; Thomas, Zakir; Bourne, Philip E. (2013). "Ten simple rules for cultivating open science and collaborative R&D". PLOS Computational Biology. 9 (9): e1003244. Bibcode:2013PLSCB...9E3244M. doi: 10.1371/journal.pcbi.1003244 . ISSN   1553-7358. PMC   3784487 . PMID   24086123.
  7. ↑ Morgan, Maxwell Robert; Roberts, Owen Gwilym; Edwards, Aled Morgan (2018). "Ideation and implementation of an open science drug discovery business model - M4K Pharma". Wellcome Open Research. 3: 154. doi: 10.12688/wellcomeopenres.14947.1 . ISSN   2398-502X. PMC   6346698 . PMID   30705971.
  8. 1 2 Harding, Rachel J. (January 2019). "Open notebook science can maximize impact for rare disease projects". PLOS Biology. 17 (1): e3000120. doi: 10.1371/journal.pbio.3000120 . ISSN   1545-7885. PMC   6366684 . PMID   30689629.
  9. 1 2 Schapira, Matthieu; Harding, Rachel J. (2019-04-02). "Open laboratory notebooks: good for science, good for society, good for scientists". F1000Research. 8: 87. doi: 10.12688/f1000research.17710.2 . ISSN   2046-1402. PMC   6694453 . PMID   31448096.
  10. 1 2 3 4 Müller, Susanne; Ackloo, Suzanne; Arrowsmith, Cheryl H.; Bauser, Marcus; Baryza, Jeremy L.; Blagg, Julian; Böttcher, Jark; Bountra, Chas; Brown, Peter J.; Bunnage, Mark E.; Carter, Adrian J. (20 April 2018). "Donated chemical probes for open science". eLife. 7. doi: 10.7554/eLife.34311 . ISSN   2050-084X. PMC   5910019 . PMID   29676732.
  11. ↑ Drewry, David H.; Wells, Carrow I.; Zuercher, William J.; Willson, Timothy M. (June 2019). "A Perspective on Extreme Open Science: Companies Sharing Compounds without Restriction". SLAS Discovery. 24 (5): 505–514. doi:10.1177/2472555219838210. ISSN   2472-5560. PMC   6624833 . PMID   31034310.
  12. 1 2 3 4 Wells, Carrow I.; Al-Ali, Hassan; Andrews, David M.; Asquith, Christopher R. M.; Axtman, Alison D.; Dikic, Ivan; Ebner, Daniel; Ettmayer, Peter; Fischer, Christian; Frederiksen, Mathias; Futrell, Robert E. (2021-01-08). "The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification". International Journal of Molecular Sciences. 22 (2): 566. doi: 10.3390/ijms22020566 . ISSN   1422-0067. PMC   7826789 . PMID   33429995.
  13. 1 2 3 4 Laflamme, Carl; McKeever, Paul M.; Kumar, Rahul; Schwartz, Julie; Kolahdouzan, Mahshad; Chen, Carol X.; You, Zhipeng; Benaliouad, Faiza; Gileadi, Opher; McBride, Heidi M.; Durcan, Thomas M. (15 October 2019). "Implementation of an antibody characterization procedure and application to the major ALS/FTD disease gene C9ORF72". eLife. 8. doi: 10.7554/eLife.48363 . ISSN   2050-084X. PMC   6794092 . PMID   31612854.
  14. 1 2 3 Ensan, Deeba; Smil, David; Zepeda-Velázquez, Carlos A.; Panagopoulos, Dimitrios; Wong, Jong Fu; Williams, Eleanor P.; Adamson, Roslin; Bullock, Alex N.; Kiyota, Taira; Aman, Ahmed; Roberts, Owen G. (2020-05-14). "Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma". Journal of Medicinal Chemistry. 63 (9): 4978–4996. doi: 10.1021/acs.jmedchem.0c00395 . ISSN   1520-4804. PMC   8213057 . PMID   32369358.
  15. ↑ Gold, E. Richard (June 2021). "The fall of the innovation empire and its possible rise through open science". Research Policy. 50 (5): 104226. doi: 10.1016/j.respol.2021.104226 . PMC   8024784 . PMID   34083844.
  16. ↑ Jones, Molly Morgan; Chataway, Joanna (2021-03-04). "The Structural Genomics Consortium: successful organisational technology experiment or new institutional infrastructure for health research?". Technology Analysis & Strategic Management. 33 (3): 296–306. doi: 10.1080/09537325.2021.1882673 . ISSN   0953-7325. S2CID   232245414.
  17. 1 2 "Structure Gallery". SGC. Retrieved 2020-09-09.
  18. ↑ Collins, Patrick M.; Douangamath, Alice; Talon, Romain; Dias, Alexandre; Brandao-Neto, Jose; Krojer, Tobias; von Delft, Frank (2018). "Achieving a Good Crystal System for Crystallographic X-Ray Fragment Screening". Modern Approaches in Drug Discovery. Methods in Enzymology. Vol. 610. pp. 251–264. doi:10.1016/bs.mie.2018.09.027. ISBN   9780128153833. ISSN   1557-7988. PMID   30390801. S2CID   53219679.
  19. ↑ Arrowsmith, Cheryl H.; Bountra, Chas; Fish, Paul V.; Lee, Kevin; Schapira, Matthieu (2012-04-13). "Epigenetic protein families: a new frontier for drug discovery". Nature Reviews. Drug Discovery. 11 (5): 384–400. doi: 10.1038/nrd3674 . ISSN   1474-1784. PMID   22498752. S2CID   5478921.
  20. ↑ Huston, Andrea; Arrowsmith, Cheryl H.; Knapp, Stefan; Schapira, Matthieu (August 2015). "Probing the epigenome". Nature Chemical Biology. 11 (8): 542–545. doi:10.1038/nchembio.1871. ISSN   1552-4469. PMID   26196765.
  21. 1 2 César-Razquin, Adrián; Snijder, Berend; Frappier-Brinton, Tristan; Isserlin, Ruth; Gyimesi, Gergely; Bai, Xiaoyun; Reithmeier, Reinhart A.; Hepworth, David; Hediger, Matthias A.; Edwards, Aled M.; Superti-Furga, Giulio (2015-07-30). "A Call for Systematic Research on Solute Carriers". Cell. 162 (3): 478–487. doi: 10.1016/j.cell.2015.07.022 . ISSN   1097-4172. PMID   26232220. S2CID   15427088.
  22. 1 2 3 4 Superti-Furga, Giulio; Lackner, Daniel; Wiedmer, Tabea; Ingles-Prieto, Alvaro; Barbosa, Barbara; Girardi, Enrico; Goldmann, Ulrich; Gürtl, Bettina; Klavins, Kristaps; Klimek, Christoph; Lindinger, Sabrina (July 2020). "The RESOLUTE consortium: unlocking SLC transporters for drug discovery". Nature Reviews. Drug Discovery. 19 (7): 429–430. doi: 10.1038/d41573-020-00056-6 . hdl: 21.11116/0000-0006-0FF1-A . ISSN   1474-1784. PMID   32265506. S2CID   215406274.
  23. ↑ Liu, Lihua; Damerell, David R.; Koukouflis, Leonidas; Tong, Yufeng; Marsden, Brian D.; Schapira, Matthieu (15 August 2019). "UbiHub: a data hub for the explorers of ubiquitination pathways". Bioinformatics. 35 (16): 2882–2884. doi:10.1093/bioinformatics/bty1067. ISSN   1367-4811. PMC   6691330 . PMID   30601939.
  24. 1 2 Schapira, Matthieu; Calabrese, Matthew F.; Bullock, Alex N.; Crews, Craig M. (December 2019). "Targeted protein degradation: expanding the toolbox". Nature Reviews. Drug Discovery. 18 (12): 949–963. doi:10.1038/s41573-019-0047-y. ISSN   1474-1784. PMID   31666732. S2CID   204942300.
  25. ↑ Harding, Rachel J.; Ferreira de Freitas, Renato; Collins, Patrick; Franzoni, Ivan; Ravichandran, Mani; Ouyang, Hui; Juarez-Ornelas, Kevin A.; Lautens, Mark; Schapira, Matthieu; von Delft, Frank; Santhakumar, Vjayaratnam (9 November 2017). "Small Molecule Antagonists of the Interaction between the Histone Deacetylase 6 Zinc-Finger Domain and Ubiquitin". Journal of Medicinal Chemistry. 60 (21): 9090–9096. doi:10.1021/acs.jmedchem.7b00933. ISSN   1520-4804. PMID   29019676.
  26. ↑ Ferreira de Freitas, Renato; Harding, Rachel J.; Franzoni, Ivan; Ravichandran, Mani; Mann, Mandeep K.; Ouyang, Hui; Lautens, Mark; Santhakumar, Vijayaratnam; Arrowsmith, Cheryl H.; Schapira, Matthieu (24 May 2018). "Identification and Structure-Activity Relationship of HDAC6 Zinc-Finger Ubiquitin Binding Domain Inhibitors". Journal of Medicinal Chemistry. 61 (10): 4517–4527. doi:10.1021/acs.jmedchem.8b00258. ISSN   1520-4804. PMID   29741882.
  27. ↑ Mann, Mandeep K.; Franzoni, Ivan; de Freitas, Renato Ferreira; Tempel, Wolfram; Houliston, Scott; Smith, Leanna; Vedadi, Masoud; Arrowsmith, Cheryl H.; Harding, Rachel J.; Schapira, Matthieu (27 November 2019). "Discovery of Small Molecule Antagonists of the USP5 Zinc Finger Ubiquitin-Binding Domain" (PDF). Journal of Medicinal Chemistry. 62 (22): 10144–10155. doi:10.1021/acs.jmedchem.9b00988. ISSN   1520-4804. PMID   31663737. S2CID   204975079.
  28. ↑ Knapp, Stefan; Arruda, Paulo; Blagg, Julian; Burley, Stephen; Drewry, David H.; Edwards, Aled; Fabbro, Doriano; Gillespie, Paul; Gray, Nathanael S.; Kuster, Bernhard; Lackey, Karen E. (January 2013). "A public-private partnership to unlock the untargeted kinome". Nature Chemical Biology. 9 (1): 3–6. doi:10.1038/nchembio.1113. ISSN   1552-4469. PMID   23238671.
  29. 1 2 3 Drewry, David H.; Wells, Carrow I.; Andrews, David M.; Angell, Richard; Al-Ali, Hassan; Axtman, Alison D.; Capuzzi, Stephen J.; Elkins, Jonathan M.; Ettmayer, Peter; Frederiksen, Mathias; Gileadi, Opher (2017). "Progress towards a public chemogenomic set for protein kinases and a call for contributions". PLOS ONE. 12 (8): e0181585. Bibcode:2017PLoSO..1281585D. doi: 10.1371/journal.pone.0181585 . ISSN   1932-6203. PMC   5540273 . PMID   28767711.
  30. ↑ "ChromoHub". chromohub.thesgc.org. Retrieved 2020-09-09.
  31. ↑ "UbiHub". ubihub.thesgc.org. Retrieved 2020-09-09.
  32. 1 2 Wu, Qin; Heidenreich, David; Zhou, Stanley; Ackloo, Suzanne; Krämer, Andreas; Nakka, Kiran; Lima-Fernandes, Evelyne; Deblois, Genevieve; Duan, Shili; Vellanki, Ravi N.; Li, Fengling (23 April 2019). "A chemical toolbox for the study of bromodomains and epigenetic signaling". Nature Communications. 10 (1): 1915. Bibcode:2019NatCo..10.1915W. doi:10.1038/s41467-019-09672-2. ISSN   2041-1723. PMC   6478789 . PMID   31015424.
  33. 1 2 Scheer, Sebastian; Ackloo, Suzanne; Medina, Tiago S.; Schapira, Matthieu; Li, Fengling; Ward, Jennifer A.; Lewis, Andrew M.; Northrop, Jeffrey P.; Richardson, Paul L.; Kaniskan, H. Ümit; Shen, Yudao (3 January 2019). "A chemical biology toolbox to study protein methyltransferases and epigenetic signaling". Nature Communications. 10 (1): 19. Bibcode:2019NatCo..10...19S. doi:10.1038/s41467-018-07905-4. ISSN   2041-1723. PMC   6318333 . PMID   30604761.
  34. ↑ Frye, Stephen V. (March 2010). "The art of the chemical probe". Nature Chemical Biology. 6 (3): 159–161. doi:10.1038/nchembio.296. ISSN   1552-4469. PMID   20154659.
  35. 1 2 Arrowsmith, Cheryl H.; Audia, James E.; Austin, Christopher; Baell, Jonathan; Bennett, Jonathan; Blagg, Julian; Bountra, Chas; Brennan, Paul E.; Brown, Peter J.; Bunnage, Mark E.; Buser-Doepner, Carolyn (August 2015). "The promise and peril of chemical probes". Nature Chemical Biology. 11 (8): 536–541. doi:10.1038/nchembio.1867. ISSN   1552-4469. PMC   4706458 . PMID   26196764.
  36. ↑ Blagg, Julian; Workman, Paul (14 August 2017). "Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology". Cancer Cell. 32 (2): 268–270. doi:10.1016/j.ccell.2017.07.010. ISSN   1878-3686. PMC   5559281 . PMID   28810148.
  37. ↑ Antolin, Albert A.; Tym, Joseph E.; Komianou, Angeliki; Collins, Ian; Workman, Paul; Al-Lazikani, Bissan (15 February 2018). "Objective, Quantitative, Data-Driven Assessment of Chemical Probes". Cell Chemical Biology. 25 (2): 194–205.e5. doi:10.1016/j.chembiol.2017.11.004. ISSN   2451-9448. PMC   5814752 . PMID   29249694.
  38. ↑ Antolin, Albert A.; Workman, Paul; Al-Lazikani, Bissan (2019-11-28). "Public resources for chemical probes: the journey so far and the road ahead". Future Medicinal Chemistry. 13 (8): 731–747. doi: 10.4155/fmc-2019-0231 . ISSN   1756-8927. PMID   31778323.
  39. ↑ Picaud, Sarah; Da Costa, David; Thanasopoulou, Angeliki; Filippakopoulos, Panagis; Fish, Paul V.; Philpott, Martin; Fedorov, Oleg; Brennan, Paul; Bunnage, Mark E.; Owen, Dafydd R.; Bradner, James E. (2013-06-01). "PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains". Cancer Research. 73 (11): 3336–3346. doi:10.1158/0008-5472.CAN-12-3292. ISSN   1538-7445. PMC   3673830 . PMID   23576556.
  40. ↑ Filippakopoulos, Panagis; Qi, Jun; Picaud, Sarah; Shen, Yao; Smith, William B.; Fedorov, Oleg; Morse, Elizabeth M.; Keates, Tracey; Hickman, Tyler T.; Felletar, Ildiko; Philpott, Martin (2010-12-23). "Selective inhibition of BET bromodomains". Nature. 468 (7327): 1067–1073. Bibcode:2010Natur.468.1067F. doi:10.1038/nature09504. ISSN   1476-4687. PMC   3010259 . PMID   20871596.
  41. ↑ Liu, Feng; Barsyte-Lovejoy, Dalia; Li, Fengling; Xiong, Yan; Korboukh, Victoria; Huang, Xi-Ping; Allali-Hassani, Abdellah; Janzen, William P.; Roth, Bryan L.; Frye, Stephen V.; Arrowsmith, Cheryl H. (2013-11-14). "Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP". Journal of Medicinal Chemistry. 56 (21): 8931–8942. doi:10.1021/jm401480r. ISSN   1520-4804. PMC   3880643 . PMID   24102134.
  42. ↑ Konze, Kyle D.; Ma, Anqi; Li, Fengling; Barsyte-Lovejoy, Dalia; Parton, Trevor; Macnevin, Christopher J.; Liu, Feng; Gao, Cen; Huang, Xi-Ping; Kuznetsova, Ekaterina; Rougie, Marie (2013). "An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1". ACS Chemical Biology. 8 (6): 1324–1334. doi:10.1021/cb400133j. ISSN   1554-8937. PMC   3773059 . PMID   23614352.
  43. ↑ Bonday, Zahid Q.; Cortez, Guillermo S.; Grogan, Michael J.; Antonysamy, Stephen; Weichert, Ken; Bocchinfuso, Wayne P.; Li, Fengling; Kennedy, Steven; Li, Binghui; Mader, Mary M.; Arrowsmith, Cheryl H. (2018-04-23). "LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity". ACS Medicinal Chemistry Letters. 9 (7): 612–617. doi:10.1021/acsmedchemlett.8b00014. ISSN   1948-5875. PMC   6047023 . PMID   30034588.
  44. ↑ Duncan, Kenneth W.; Rioux, Nathalie; Boriack-Sjodin, P. Ann; Munchhof, Michael J.; Reiter, Lawrence A.; Majer, Christina R.; Jin, Lei; Johnston, L. Danielle; Chan-Penebre, Elayne; Kuplast, Kristy G.; Porter Scott, Margaret (2016-02-11). "Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666". ACS Medicinal Chemistry Letters. 7 (2): 162–166. doi:10.1021/acsmedchemlett.5b00380. ISSN   1948-5875. PMC   4753547 . PMID   26985292.
  45. ↑ Grebien, Florian; Vedadi, Masoud; Getlik, Matthäus; Giambruno, Roberto; Grover, Amit; Avellino, Roberto; Skucha, Anna; Vittori, Sarah; Kuznetsova, Ekaterina; Smil, David; Barsyte-Lovejoy, Dalia (August 2015). "Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia". Nature Chemical Biology. 11 (8): 571–578. doi:10.1038/nchembio.1859. ISSN   1552-4469. PMC   4511833 . PMID   26167872.
  46. ↑ Roskoski, Robert (June 2019). "Properties of FDA-approved small molecule protein kinase inhibitors". Pharmacological Research. 144: 19–50. doi:10.1016/j.phrs.2019.03.006. ISSN   1096-1186. PMID   30877063. S2CID   80625382.
  47. ↑ Wilson, LJ; et, al. (2018). "New Perspectives, Opportunitiess, and Challenges in Exploring the Human Protein Kinome". Cancer Research. 78 (1): 15–29. doi: 10.1158/0008-5472.CAN-17-2291 . PMID   29254998.
  48. ↑ Sorget, Nienke; et, al (2020). "Exploring the understudied human kinome for research and therapeutic opportunities" (PDF). www.biorxiv.org. doi:10.1101/2020.04.02.022277. S2CID   215404186.
  49. ↑ Buljan, M; et, al. (2020). "Kinase Interaction Network Expands Functional and Disease Roles of Human Kinases". Molecular Cell. 79 (3): 504–520.e9. doi: 10.1016/j.molcel.2020.07.001 . PMC   7427327 . PMID   32707033. S2CID   220746851.
  50. ↑ "Target Enabling Packages (TEPs)". SGC. 2016-06-13. Retrieved 2020-09-09.
  51. 1 2 Edwards, Aled M.; Arrowsmith, Cheryl H.; Bountra, Chas; Bunnage, Mark E.; Feldmann, Marc; Knight, Julian C.; Patel, Dhavalkumar D.; Prinos, Panagiotis; Taylor, Michael D.; Sundström, Michael; SGC Open Source Target-Discovery Partnership (March 2015). "Preclinical target validation using patient-derived cells". Nature Reviews. Drug Discovery. 14 (3): 149–150. doi:10.1038/nrd4565. ISSN   1474-1784. PMID   25722227. S2CID   2423838.
  52. ↑ "Viral Interruption Medicines Initiative (VIMI)". Viral Interruption Medicines Initiative (VIMI). Retrieved 2021-03-21.
  53. ↑ Hoag, Hannah (2009). "Richard Gold". Nature Biotechnology. 27 (5): 409. doi: 10.1038/nbt0509-409 . ISSN   1546-1696. PMID   19430435. S2CID   34394262.
  54. ↑ Edwards, Aled; Morgan, Max; Al Chawaf, Arij; Andrusiak, Kerry; Charney, Rachel; Cynader, Zarya; ElDessouki, Ahmed; Lee, Yunjeong; Moeser, Andrew; Stern, Simon; Zuercher, William J. (31 May 2017). "A trust approach for sharing research reagents". Science Translational Medicine. 9 (392): eaai9055. doi: 10.1126/scitranslmed.aai9055 . ISSN   1946-6242. PMID   28566431. S2CID   4020927.
  55. ↑ "Chemical Probes". SGC. 2019-04-08. Retrieved 2020-09-09.
  56. ↑ Harding, Rachel (19 October 2016). "An Open Approach to Huntington's Disease Research". nature blogs.
  57. ↑ Vedadi, Masoud; Lew, Jocelyne; Artz, Jennifer; Amani, Mehrnaz; Zhao, Yong; Dong, Aiping; Wasney, Gregory A.; Gao, Mian; Hills, Tanya; Brokx, Stephen; Qiu, Wei (January 2007). "Genome-scale protein expression and structural biology of Plasmodium falciparum and related Apicomplexan organisms". Molecular and Biochemical Parasitology. 151 (1): 100–110. doi:10.1016/j.molbiopara.2006.10.011. ISSN   0166-6851. PMID   17125854.
  58. ↑ Frye, Stephen V.; Arkin, Michelle R.; Arrowsmith, Cheryl H.; Conn, P. Jeffrey; Glicksman, Marcie A.; Hull-Ryde, Emily A.; Slusher, Barbara S. (November 2015). "Tackling reproducibility in academic preclinical drug discovery". Nature Reviews. Drug Discovery. 14 (11): 733–734. doi:10.1038/nrd4737. ISSN   1474-1784. PMID   26388229. S2CID   205478934.
  59. 1 2 3 Marcon, Edyta; Jain, Harshika; Bhattacharya, Anandi; Guo, Hongbo; Phanse, Sadhna; Pu, Shuye; Byram, Gregory; Collins, Ben C.; Dowdell, Evan; Fenner, Maria; Guo, Xinghua (August 2015). "Assessment of a method to characterize antibody selectivity and specificity for use in immunoprecipitation". Nature Methods. 12 (8): 725–731. doi:10.1038/nmeth.3472. ISSN   1548-7105. PMID   26121405. S2CID   205423964.
  60. ↑ Gruetter, Markus (2012). "Open collaboration is key to new drugs". Nature. 491 (7422): 40. doi: 10.1038/491040d . ISSN   0028-0836. PMID   23128216. S2CID   205074791.
  61. ↑ Carter, Adrian J.; Kraemer, Oliver; Zwick, Matthias; Mueller-Fahrnow, Anke; Arrowsmith, Cheryl H.; Edwards, Aled M. (November 2019). "Target 2035: probing the human proteome". Drug Discovery Today. 24 (11): 2111–2115. doi: 10.1016/j.drudis.2019.06.020 . ISSN   1878-5832. PMID   31278990.
  62. ↑ Schapira, Matthieu; Tyers, Mike; Torrent, Maricel; Arrowsmith, Cheryl H. (November 2017). "WD40 repeat domain proteins: a novel target class?". Nature Reviews. Drug Discovery. 16 (11): 773–786. doi:10.1038/nrd.2017.179. ISSN   1474-1784. PMC   5975957 . PMID   29026209.
  63. ↑ Song, Richard; Wang, Zhong-Duo; Schapira, Matthieu (6 October 2017). "Disease Association and Druggability of WD40 Repeat Proteins". Journal of Proteome Research. 16 (10): 3766–3773. doi:10.1021/acs.jproteome.7b00451. ISSN   1535-3907. PMID   28956604.
  64. ↑ Wang, Jiayan; Yazdani, Setayesh; Han, Ana; Schapira, Matthieu (March 2020). "Structure-based view of the druggable genome". Drug Discovery Today. 25 (3): 561–567. doi:10.1016/j.drudis.2020.02.006. ISSN   1878-5832. PMID   32084498. S2CID   211246313.
  65. ↑ Wacker, Daniel; Stevens, Raymond C.; Roth, Bryan L. (2017-07-27). "How Ligands Illuminate GPCR Molecular Pharmacology". Cell. 170 (3): 414–427. doi:10.1016/j.cell.2017.07.009. ISSN   1097-4172. PMC   5560499 . PMID   28753422.
  66. ↑ Roth, Bryan L.; Irwin, John J.; Shoichet, Brian K. (November 2017). "Discovery of new GPCR ligands to illuminate new biology". Nature Chemical Biology. 13 (11): 1143–1151. doi:10.1038/nchembio.2490. ISSN   1552-4469. PMC   5835362 . PMID   29045379.
  67. ↑ Roth, Bryan L. (August 2019). "How structure informs and transforms chemogenetics". Current Opinion in Structural Biology. 57: 9–16. doi:10.1016/j.sbi.2019.01.016. ISSN   1879-033X. PMID   30818201. S2CID   73479428.
  68. ↑ Edwards, Aled (2016-03-17). "Reproducibility: Team up with industry". Nature. 531 (7594): 299–301. Bibcode:2016Natur.531..299E. doi: 10.1038/531299a . ISSN   1476-4687. PMID   26983524. S2CID   4467772.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.